OSAKA, Japan, Nov. 28, 2016 /PRNewswire/ -- Santen Pharmaceutical Co., Ltd. (hereinafter, "Santen"), a specialty ophthalmology company headquartered in Osaka, Japan, today announced the topline results of its SAKURA ( Sirolimus study Assessing double-mas Ked Uveitis t Re Atment) global clinical development program designed to confirm the efficacy, safety, and optimal dose between three active doses of sirolimus intravitreal injection as monotherapy for patients with non-infectious uveitis of the posterior segment. The SAKURA Program met its objective, demonstrating that OPSIRIA (440 µg sirolimus injection, development code: DE-109) can effectively and safely reduce intraocular inflammation (as measured by vitreous haze).
Findings from SAKURA Study 1, the first Phase III trial, established the efficacy and safety of OPSIRIA as a potential treatment for non-infectious uveitis of the posterior segment. In SAKURA Study 2, the second Phase III trial, the difference in the effect (vitreous haze) between the low dose of sirolimus injection (44 µg) and OPSIRIA was not statistically significant, though clinical findings provide supportive evidence confirming the efficacy of the product. Based on the totality of the data from the SAKURA Program, Santen plans to file a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA). "OPSIRIA will address a significant need in the management of non-infectious uveitis of the posterior segment as a locally-delivered option for this orphan disease. Santen is looking forward to filing an NDA in the U.S. in early 2017," said Naveed Shams, MD, PhD, Chief Scientific Officer and Head of Global Research and Development at Santen. About SAKURA The SAKURA Program is the largest Phase III global clinical program to date evaluating patients with non-infectious uveitis of the posterior segment. Both SAKURA Study 1 and Study 2 were multinational, randomized and double-masked, assessing the efficacy and safety of OPSIRIA as monotherapy in patients with non-infectious uveitis of the posterior segment. The primary endpoint of the studies was to achieve a vitreous haze score 1 of zero at month five. SAKURA Studies 1 and 2 enrolled patients under the same protocol through six months of treatment. Eligible patients were randomized into one of three active treatment arms (44 µg, 440 µg, 880 µg). About OPSIRIA OPSIRIA (440 µg sirolimus injection) is a first-in-class intravitreal, locally-delivered, targeted, immunoregulator being investigated for the treatment of non-infectious uveitis of the posterior segment - a progressive and chronic inflammatory disease of the eye. OPSIRIA regulates the immune system through the inhibition of mTOR which acts by interrupting the inflammatory cascade that leads to T-cell activation, differentiation and proliferation, and production of interleukin-2 (IL-2), as well as other pro-inflammatory cytokines and, also, promoting immune tolerance by inducing T regulatory cells (Tregs).